Cited by Emerging evidence on heterologous COVID-19 vaccine schedules

High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron DOI

Ulrike Baum, Eero Poukka, Tuija Leino

et al.

BMC Infectious Diseases, Journal Year: 2022, Volume and Issue: 22(1)

Published: Nov. 5, 2022

The elderly are highly vulnerable to severe COVID-19. Waning immunity and emergence of Omicron have caused concerns about reduced effectiveness COVID-19 vaccines. objective was estimate vaccine (VE) against among the elderly.This nationwide, register-based cohort analysis included all residents aged 70 years over in Finland. follow-up started on December 27, 2020, ended March 31, 2022. outcomes interest were COVID-19-related hospitalization intensive care unit (ICU) admission timely associated with SARS-CoV-2 infection. VE estimated as one minus hazard ratio comparing vaccinated unvaccinated taking into account time since vaccination. Omicron-specific evaluated observed January 1, 2022.The 896,220 individuals. Comirnaty (BioNTech/Pfizer) 93% (95% CI 89-95%) 85% 82-87%) 14-90 91-180 days after second dose; increased 95% 94-96%) 14-60 third dose. other homologous heterologous three dose series similar. Protection requiring ICU treatment even better. Since 2022, 98% 92-99%) 92% 87-95%) 95-99%) dose.VE is high elderly. It waned slightly two doses, but a restored protection. remained Omicron.

Language: Английский

Citations

Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens DOI

Shona C. Moore, Barbara Kronsteiner,

Stephanie Longet

et al.

Med, Journal Year: 2023, Volume and Issue: 4(3), P. 191 - 215.e9

Published: Feb. 16, 2023

Both infection and vaccination, alone or in combination, generate antibody T cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the maintenance of such responses-and hence protection from disease-requires careful characterization. In a large prospective study UK healthcare workers (HCWs) (Protective Immunity Cells Healthcare Workers [PITCH], within larger SARS-CoV-2 Reinfection Evaluation [SIREN] study), we previously observed that prior strongly affected subsequent cellular humoral immunity induced after long short dosing intervals BNT162b2 (Pfizer/BioNTech) vaccination.

Language: Английский

Citations

A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines DOI

Xiao‐Feng He,

Jiao Su,

Yunan Ma

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Aug. 26, 2022

It is urgently needed to update the comprehensive analysis about efficacy or effectiveness of COVID-19 vaccines especially during pandemic caused by SARS-CoV-2 Delta and Omicron variants. In general, current showed a cumulative 66.4%, 79.7%, 93.6% prevent infection, symptomatic COVID-19, severe respectively, but could not asymptomatic infection SARS-CoV-2. Furthermore, effectively variant although incidence breakthrough increased when intervals post full vaccination extended, suggesting waning vaccines. addition, one-dose booster immunization an 74.5% variant. However, sub-lineage BA.1.1.529 had 50% BA.1.1.529. was 87.6% 90.1% COVID-19-related death BA.2, while enhance BA.2. Two-dose 81.8% against compared with immunization. The RNA-based vaccine BNT162b2 mRNA-1273 over 75% more than 17 weeks after whereas heterogenous better homologous summary, protect variants less effective infection. One-dose protection capability, two-dose provide additional COVID-19.

Language: Английский

Citations

Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021 DOI

Jostein Starrfelt, Anders Skyrud Danielsen, Eirik Alnes Buanes

et al.

BMC Medicine, Journal Year: 2022, Volume and Issue: 20(1)

Published: Sept. 2, 2022

Abstract Background COVID-19 vaccines have been crucial in the pandemic response and understanding changes effectiveness is essential to guide vaccine policies. Although Delta variant no longer dominant, properties will provide knowledge comprehend development of estimate potential over time. Methods In this population-based cohort study, we estimated Comirnaty (Pfizer/BioNTech; BNT162b2), Spikevax (Moderna; mRNA-1273), Vaxzevria (AstraZeneca; ChAdOx nCoV-19; AZD1222), or a combination against SARS-CoV-2 infections, hospitalisations, intensive care admissions, death using Cox proportional hazard models, across different product regimens age groups, between 15 July 31 November 2021 (Delta period). Vaccine status included as time-varying covariate all models were adjusted for age, sex, comorbidities, county residence, country birth, living conditions. Data from entire adult Norwegian population collated National Preparedness Register (Beredt C19). Results The overall infection decreased 81.3% (confidence interval (CI): 80.7 81.9) first 2 9 weeks after receiving second dose 8.6% (CI: 4.0 13.1) more than 33 weeks, compared 98.6% 97.5 99.2) 66.6% 57.9 73.6) hospitalisation respectively. After third (booster), was 75.9% 73.4 78.1) 95.0% 92.6 96.6) hospitalisation. mRNA products provided highest protection, but with time since vaccination regimens. Conclusions Even though waned time, remained effective dose. For regimens, booster facilitated recovery effectiveness. results support use heterologous schedules, increasing flexibility policy.

Language: Английский

Citations

Emerging evidence on heterologous COVID-19 vaccine schedules—To mix or not to mix? DOI

Edward P K Parker,

Shalini Desai,

Melanie Marti

et al.

The Lancet Infectious Diseases, Journal Year: 2022, Volume and Issue: 22(4), P. 438 - 440

Published: March 9, 2022

Language: Английский

Citations